Skip to content

US · LEXX · BIOTECHNOLOGY

Lexaria Bioscience Corp. (LEXX) intrinsic value and stock valuation

$4.03as of 2026-11-21 · Mkt cap 8.71M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lexaria Bioscience Corp. DCF and intrinsic value

InvestorsCraft values LEXX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LEXX’s statements →

Lexaria Bioscience Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Kelowna, BC V1X 2P7 lexariabioscience.com

How the business is doing

Fiscal 2010–2025, USD

Revenue
$710K+13.3% 5y CAGRd
20102025
Net income
-$-11.9M
20102025
Free cash flow
-$-10.48M
20102025
Total equity
$2.6M+0.9% 5y CAGRd
20102025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2010–2025, USD
20252024202320222021
Revenue$710K$460K$230K$260K$720K
Operating income-$-11.88M-$-5.75M-$-6.53M-$-6.62M-$-5.69M
Net income-$-11.9M-$-5.8M-$-6.66M-$-7.27M-$-4.03M
EPSd-$-9.92M-$-6.99M-$-15.14M-$-18.64M-$-13.9M
Operating cash flow-$-10.45M-$-4.96M-$-5.88M-$-4.88M-$-3.99M
Capital expenditure-$-20K-$-40K-$-170K-$-50K-$-80K
Free cash flow-$-10.48M-$-5M-$-6.05M-$-4.93M-$-4.07M
Total assets$4.18M$8.87M$3.08M$7.83M$13.3M
Total debt$110K$140K$160K$50K$100K
Net debt-$-1.69M-$-6.36M-$-1.19M-$-5.76M-$-10.82M
Total equity$2.6M$7.66M$2.68M$7.63M$13.1M
Cash and short-term investments$1.97M$6.56M$1.48M$6.16M$11.8M
Income statement
20252024202320222021
Revenue$710K$460K$230K$260K$720K
Cost of revenue$0.00$0.00$30K$70K$180K
Gross profit$700K$460K$190K$180K$550K
Research and development expenses$8.24M$2.36M$3.67M$1.84M$1.26M
Selling, general and administrative expenses$4.35M$3.85M$3.06M$4.96M$4.97M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$12.6M$6.21M$6.73M$6.8M$6.23M
Cost and expenses$12.6M$6.22M$6.76M$6.87M$6.41M
Interest income$0.00$10K$40K$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$90K$80K$150K$100K$150K
Ebitda-$-11.82M-$-5.73M-$-6.57M-$-7.28M-$-4.02M
Operating income-$-11.88M-$-5.75M-$-6.53M-$-6.62M-$-5.69M
Total other income/expenses, net-$-30K-$-60K-$-180K-$-760K$1.52M
Income before tax-$-11.91M-$-5.81M-$-6.71M-$-7.38M-$-4.16M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-11.9M-$-5.8M-$-6.66M-$-7.27M-$-4.03M
Weighted average shares outstanding$1.2M$830K$440K$390K$290K
Weighted average diluted shares outstanding$1.2M$830K$440K$390K$290K
Balance sheet
20252024202320222021
Cash and short-term investments$1.97M$6.56M$1.48M$6.16M$11.8M
Net receivables$170K$150K$180K$200K$340K
Inventory$0.00$0.00$0.00$40K$30K
Total current assets$3.47M$7.9M$2.2M$6.98M$12.4M
Property, plant and equipment, net$330K$390K$420K$370K$460K
Goodwill and intangible assets$310K$520K$460K$490K$360K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$710K$970K$880K$860K$820K
Total assets$4.18M$8.87M$3.08M$7.83M$13.3M
Accounts payable$1.37M$1.06M$230K$120K$100K
Short-term debt$30K$30K$30K$40K$50K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.49M$1.1M$270K$190K$150K
Long-term debt$80K$110K$140K$10K$50K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$80K$110K$140K$10K$50K
Capital lease obligations$110K$140K$160K$50K$90K
Total liabilities$1.57M$1.21M$400K$200K$200K
Common stock$20K$20K$10K$10K$10K
Retained earnings-$-63.46M-$-51.56M-$-45.76M-$-39.1M-$-31.83M
Accumulated other comprehensive income (loss)-$-70K-$-20K$0.00$0.00$0.00
Total equity$2.6M$7.66M$2.68M$7.63M$13.1M
Total investments$170K$60K$130K$350K$830K
Total debt$110K$140K$160K$50K$100K
Net debt-$-1.69M-$-6.36M-$-1.19M-$-5.76M-$-10.82M
Cash flow statement
20252024202320222021
Net income-$-11.91M-$-5.81M-$-6.71M-$-7.38M-$-4.19M
Depreciation and amortization$90K$80K$150K$100K$150K
Stock-based compensation$860K$490K$170K$750K$410K
Change in working capital$200K$110K$140K-$-350K$60K
Accounts receivable-$-210K-$-50K$30K-$-140K$190K
Inventory$0.00$0.00$40K-$0.00$100K
Accounts payable$0.00$830K$90K$50K$10K
Net cash provided by operating activities-$-10.45M-$-4.96M-$-5.88M-$-4.88M-$-3.99M
Investments in property, plant and equipment-$-20K-$-40K-$-30K-$-50K-$-80K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-240K-$-190K-$-170K-$-180K$190K
Common stock issued$6.05M$4.21M$1.59M$0.00$9.47M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.05M$10.3M$1.59M-$-40K$13.4M
Net change in cash-$-4.7M$5.15M-$-4.46M-$-5.1M$9.62M
Cash at end of period$1.8M$6.5M$1.35M$5.81M$10.9M
Operating cash flow-$-10.45M-$-4.96M-$-5.88M-$-4.88M-$-3.99M
Capital expenditure-$-20K-$-40K-$-170K-$-50K-$-80K
Free cash flow-$-10.48M-$-5M-$-6.05M-$-4.93M-$-4.07M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lexaria Bioscience Corp.

        Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.

        CEO
        Richard C. Christopher
        Employees
        7
        Beta
        0.34

        Explore

        Frequently asked questions

        What is the intrinsic value of Lexaria Bioscience Corp. (LEXX)?

        InvestorsCraft does not currently publish an intrinsic value for LEXX. How the IC value is calculated.

        Is LEXX undervalued?

        InvestorsCraft does not publish an undervaluation signal for LEXX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.